References
1. Ruccione KS, Wood JC, Sposto R, Malvar J, Chen C, Freyer DR. Characterization of transfusion-derived iron deposition in childhood cancer survivors. Cancer Epidemiol Biomarkers Prev 2014;23:1913-9.
2. de Ville de Goyet M, Moniotte S, Robert A, et al. Iron overload in children undergoing cancer treatments. Pediatr Blood Cancer 2013;60:1982-7.
3. Sahlstedt L, von Bonsdorff L, Ebeling F, Parkkinen J, Juvonen E, Ruutu T. Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation. Eur J Haematol 2009;83:455-9.
4. Huang KE, Mittelman SD, Coates TD, Geffner ME, Wood JC. A significant proportion of thalassemia major patients have adrenal insufficiency detectable on provocative testing. J Pediatr Hematol Oncol 2015;37:54-9.
5. Beguin Y, Aapro M, Ludwig H, Mizzen L, Osterborg A. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis–a critical review. Crit Rev Oncol Hematol 2014;89:1-15.
6. Kuo DJ, Bhagia P. Incidentally Detected Transfusion-associated Iron Overload in 3 Children After Cancer Chemotherapy. J Pediatr Hematol Oncol 2018;40:e164-e6.
7. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82.
8. Rigoli L, Petrungaro A, Di Bella C, Caruso R. Iron overload and malignancies in patients with haemoglobinopathies: A single center experience. Transfus Apher Sci 2019;58:647-51.
9. Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis 2011;47:33-40.
10. Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008;100:996-1002.
11. Coates TD. Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free radical biology & medicine 2014;72:23-40.
12. Coates TD, Wood JC. How we manage iron overload in sickle cell patients. British journal of haematology 2017;177:703-16.
13. Kazak AE, Hocking MC, Ittenbach RF, et al. A revision of the intensity of treatment rating scale: classifying the intensity of pediatric cancer treatment. Pediatr Blood Cancer 2012;59:96-9.
14. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005;106:1460-5.
15. Wood JC. Guidelines for quantifying iron overload. Hematology Am Soc Hematol Educ Program 2014;2014:210-5.
16. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-61.
17. Carpenter JP, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. Circulation 2011;123:1519-28.
18. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343:327-31.
19. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009;114:4021-6.
20. Wood JC. Estimating tissue iron burden: current status and future prospects. British journal of haematology 2015;170:15-28.
21. Noetzli LJ, Panigrahy A, Hyderi A, Dongelyan A, Coates TD, Wood JC. Pituitary iron and volume imaging in healthy controls. AJNR Am J Neuroradiol 2012;33:259-65.
22. Noetzli LJ, Panigrahy A, Mittelman SD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. American journal of hematology 2012;87:167-71.
23. Coates TD. Iron overload in transfusion-dependent patients. Hematology Am Soc Hematol Educ Program 2019;2019:337-44.
24. Ganz T. Systemic iron homeostasis. Physiological reviews 2013;93:1721-41.
25. Bradley SJ, Gosriwitana I, Srichairatanakool S, Hider RC, Porter JB. Non-transferrin-bound iron induced by myeloablative chemotherapy. British journal of haematology 1997;99:337-43.
26. Sahlstedt L, Ebeling F, von Bonsdorff L, Parkkinen J, Ruutu T. Non-transferrin-bound iron during allogeneic stem cell transplantation. British journal of haematology 2001;113:836-8.
27. Ghugre NR, Coates TD, Nelson MD, Wood JC. Mechanisms of tissue-iron relaxivity: nuclear magnetic resonance studies of human liver biopsy specimens. Magn Reson Med 2005;54:1185-93.
28. Ghugre NR, Gonzalez-Gomez I, Butensky E, et al. Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease. American journal of hematology 2009;84:480-3.
29. Ghugre NR, Gonzalez-Gomez I, Shimada H, Coates TD, Wood JC. Quantitative analysis and modelling of hepatic iron stores using stereology and spatial statistics. Journal of microscopy 2010;238:265-74.
30. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009;120:1961-8.
31. Puliyel M, Mainous AG, 3rd, Berdoukas V, Coates TD. Iron toxicity and its possible association with treatment of Cancer: lessons from hemoglobinopathies and rare, transfusion-dependent anemias. Free radical biology & medicine 2015;79:343-51.
32. Berdoukas V, Nord A, Carson S, et al. Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age. American journal of hematology 2013;88:E283-5.
33. Garbowski MW, Cabantchik I, Hershko C, Hider R, Porter JB. The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron-carbohydrate administration. American journal of hematology 2023;98:533-40.
34. Altes A, Remacha AF, Sarda P, Baiget M, Canals C, Sierra J. The relationship between transferrin saturation and erythropoiesis during stem cell transplantation. Haematologica 2006;91:992-3.
35. Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC. Pancreatic iron and glucose dysregulation in thalassemia major. American journal of hematology 2012;87:155-60.
36. Tukenova M, Diallo I, Anderson H, et al. Second malignant neoplasms in digestive organs after childhood cancer: a cohort-nested case-control study. Int J Radiat Oncol Biol Phys 2012;82:e383-90.
37. Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. Jama 2013;309:2371-81.
38. Ruccione KS, Mudambi K, Sposto R, Fridey J, Ghazarossian S, Freyer DR. Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors. Pediatr Blood Cancer 2012;59:697-702.
39. Łęcka M, Słomka A, Albrecht K, Żekanowska E, Romiszewski M, Styczyński J. Unbalance in Iron Metabolism in Childhood Leukemia Converges with Treatment Intensity: Biochemical and Clinical Analysis. Cancers 2021;13.
40. Nottage K, Gurney JG, Smeltzer M, Castellanos M, Hudson MM, Hankins JS. Trends in transfusion burden among long-term survivors of childhood hematological malignancies. Leuk Lymphoma 2013;54:1719-23.
41. Puliyel M, Sposto R, Berdoukas VA, et al. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. American journal of hematology 2014;89:391-4.
42. Taher AT, Porter JB, Viprakasit V, et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. British journal of haematology 2015;168:284-90.
43. Wilson SR, Sears M, Williams E, et al. Gaps in the diagnosis and management of iron overload in sickle cell disease: a ’real-world’ report from the GRNDaD registry. British journal of haematology 2021.
44. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 2020;4:327-55.
45. Ellervik C, Andersen HU, Tybjærg-Hansen A, et al. Total mortality by elevated transferrin saturation in patients with diabetes. Diabetes Care 2013;36:2646-54.
46. Kremastinos DT, Farmakis D, Aessopos A, et al. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circulation Heart failure 2010;3:451-8.
47. Hodroj MH, Bou-Fakhredin R, Nour-Eldine W, Noureldine HA, Noureldine MHA, Taher AT. Thalassemia and malignancy: An emerging concern? Blood Rev 2019;37:100585.
48. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. British journal of haematology 2010;148:466-75.